Immunic Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New US patent likely to cover all vidofludimus calcium doses in MS

New US patent likely to cover all vidofludimus calcium doses in MS
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel vittTrademark officeImmunic therapeuticDosage regimenChronic inflammatoryAutoimmune diseases

ACTRIMS 2023: Novel RRMS therapy offers safety and efficacy | Immunic s vidofludimus calcium may give patients a better choice

Immunic's novel RRMS treatment vidofludimus calcium may offer similar efficacy and better safety than approved MS therapies, new data shows.

San diegoUnited statesAndreas muehlerAmericas committee for treatmentResearch in multiple sclerosisImmunic therapeuticMultiple sclerosis news todayAmericas committeeMultiple sclerosisExpanded disability status scale

2 Years of Vidofludimus Calcium Thwarts Disability Progression: Data | Multiple Sclerosis News Today

2 Years of Vidofludimus Calcium Thwarts Disability Progression: Data | Multiple Sclerosis News Today
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Daniel vittImmunic therapeutic

Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS

Immunic Sets Optimal Dose of Oral IMU-838 for Phase 3 Trials in RRMS 4.8 (5) Interim data from a Phase 2 trial of Immunic Therapeutics’ investigational oral therapy IMU-838 (vidofludimus calcium) in relapsing-remitting multiple sclerosis (RRMS) patients has established a once-daily, 30 mg dose as the most appropriate for future Phase 3 trials. The company is now in discussions with regulatory authorities, including those in the U.S. and Europe, regarding pivotal Phase 3 testing expected to start later this year. At the request of the U.S. Food and Drug Administration (FDA), Immunic will directly submit an investigational new drug (IND) application for the right to open a Phase 3 trial, instead of waiting for an end-of-Phase 2 meeting, it reported in a press release.

Andreas muehlerDaniel vittUniversity of torontoUniversity of lisbonDrug administrationBiomedical sciencesImmunic therapeuticMolecular biologyUniversidade nova de lisboaManaging science editorடேனியல் விட்பல்கலைக்கழகம் ஆஃப் டொராண்டோபல்கலைக்கழகம் ஆஃப் லிஸ்பன்உயிர் மருத்துவ அறிவியல்மூலக்கூறு உயிரியல்யுனிவர்சிடேட் நோவா டி லிஸ்போவா